Dyslipidemia and risk of prostate canсer in patients with urologic diseases
https://doi.org/10.23946/2500-0764-2022-7-1-42-52
Abstract
Aim. To assess the impact of homeostasis parameters on risk of prostate cancer.
Materials and Methods. The study included 108 patients with urologic diseases and with (n = 54) or without (n = 54) prostate cancer. Median age in both groups was 67 (interquartile range 64-73) years. Clinicopathological data and blood test results have been collected from outpatient and inpatient records. In particular, we measured serum levels of total testosterone and prostate-specific antigen.
Results. Risk factors for prostate cancer include increased total cholesterol (p = 0.023), low-density lipoprotein cholesterol (p = 0.035), total triglycerides (p = 0.048), and total testosterone (p = 0.002). High levels of total testosterone directly correlated with the tumor stage (r = 0.56). The concentration of prostate-specific antigen correlated with the lipid parameters and remained a reliable diagnostic criterion (p = 0.002).
Conclusion. The association of hyper/dyslipidemia with prostate cancer provides an opportunity to improve its prevention by routine lipid screening in high-risk groups.
About the Authors
A. V. Smirnov
Kemerovo State Medical University
Russian Federation
Russian Federation
Alexey V. Smirnov, MD, PhD Student, Department of Epidemiology,
Infectious Diseases, Dermatology and Venereology
22a, Voroshilova Street, Kemerovo, 650056
O. V. Gruzdeva
Kemerovo State Medical University; Research Institute for Complex Issues of Cardiovascular Diseases
Russian Federation
Russian Federation
Olga V. Gruzdeva, MD, DSc, Associate Professor, Head of the
Laboratory for Homeostasis Research, Division of Experimental
Medicine; Professor, Department of Pathological Physiology
22a, Voroshilova Street, Kemerovo, 650056;
6, Sosnovy Boulevard, Kemerovo, 650002
E. V. Pomeshkin
Kemerovo State Medical University; Podgorbunskiy Kuzbass Clinical Emergency Hospital
Russian Federation
Russian Federation
Evgeny V. Pomeshkin, MD, PhD, Head of the Department of Urology
22a, Voroshilova Street, Kemerovo, 650056;
22, Nikolaya Ostrovskogo Street, Kemerovo, 650000
A. I. Bragin-Maltsev
Kemerovo State Medical University; Podgorbunskiy Kuzbass Clinical Emergency Hospital
Russian Federation
Russian Federation
Andrey I. Bragin-Maltsev, MD, Urologist, Department of Urology; Assistant Professor, Department of General Surgery and Urology
22a, Voroshilova Street, Kemerovo, 650056;
22, Nikolaya Ostrovskogo Street, Kemerovo, 650000
References
1. Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941-1953. https://doi.org/10.1002/ijc.31937
2. Teoh JYC, Hirai HW, Ho JMW, Chan FCH, Tsoi KKF, Ng CF. Global incidence of prostate cancer in developing and developed countries with changing age structures. PLoS One. 2019;14(10):e0221775. https://doi.org/10.1371/journal.pone.0221775
3. Pernar CH, Ebot EM, Wilson KM, Mucci LA. The Epidemiology of Prostate Cancer. Cold Spring Harb Perspect Med. 2018;8(12):a030361. https://doi.org/10.1101/cshperspect.a030361
4. Perez-Cornago A, Key TJ, Allen NE, Fensom GK, Bradbury KE, Martin RM, Travis RC. Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study. Br J Cancer. 2017;117(10):1562-1571. https://doi.org/10.1038/bjc.2017.312
5. McDowell ME, Occhipinti S, Gardiner RA, Baade PD, Steginga SK. A review of prostate-specific antigen screening prevalence and risk perceptions for first-degree relatives of men with prostate cancer. Eur J Cancer Care (Engl). 2009;18(6):545-555. https://doi.org/10.1111/j.1365-2354.2008.01046.x
6. Meissner VH, Bittner R, Kron M, Schiele S, Schulwitz H, Gschwend JE, Herkommer K. Impact of a Changing Population Structure and Clustering of Cancer in Prostate Cancer Patients Depending on a First-Degree Family History. Urol Int. 2020;104(3-4):222-229. https://doi.org/10.1159/000504789
7. Kaiser A, Haskins C, Siddiqui MM, Hussain A, D'Adamo C. The evolving role of diet in prostate cancer risk and progression. Curr Opin Oncol. 2019;31(3):222-229. https://doi.org/10.1097/CCO.0000000000000519
8. Siemińska L, Borowski A, Marek B, Nowak M, Kajdaniuk D, Warakomski J, Kos-Kudła B. Serum concentrations of adipokines in men with prostate cancer and benign prostate hyperplasia. Endokrynol Pol. 2018;69(2):120-127. https://doi.org/10.5603/EP.a2018.0006
9. Murtola TJ, Kasurinen TVJ, Talala K, Taari K, Tammela TLJ, Auvinen A. Serum cholesterol and prostate cancer risk in the Finnish randomized study of screening for prostate cancer. Prostate Cancer Prostatic Dis. 2019;22(1):66-76. https://doi.org/10.1038/s41391-018-0087-0
10. Schnoeller TJ, Jentzmik F, Schrader AJ, Steinestel J. Influence of serum cholesterol level and statin treatment on prostate cancer aggressiveness. Oncotarget. 2017;8(29):47110-47120. https://doi.org/10.18632/oncotarget.16943
11. Jamnagerwalla J, Howard LE, Allott EH, Vidal AC, Moreira DM, Castro-Santamaria R, Andriole GL, Freeman MR, Freedland SJ. Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study. Prostate Cancer Prostatic Dis. 2018;21(2):252-259. https://doi.org/10.1038/s41391-017-0030-9
12. Barbalata CI, Tefas LR, Achim M, Tomuta I, Porfire AS. Statins in risk-reduction and treatment of cancer. World J Clin Oncol. 2020;11(8):573-588. https://doi.org/10.5306/wjco.v11.i8.573
13. Wang K, Gerke TA, Chen X, Prosperi M. Association of statin use with risk of Gleason score-specific prostate cancer: A hospital-based cohort study. Cancer Med. 2019;8(17):7399-7407. https://doi.org/10.1002/cam4.2500
14. Ghoshal A, Garmo H, Hammar N, Jungner I, Malmström H, Walldius G, Van Hemelrijck M. Can pre-diagnostic serum levels of sodium and potassium predict prostate cancer survival? BMC Cancer. 2018;18(1):1169. https://doi.org/10.1186/s12885-018-5098-7
15. Cutruzzolà F, Giardina G, Marani M, Macone A, Paiardini A, Rinaldo S, Paone A. Glucose Metabolism in the Progression of Prostate Cancer. Front Physiol. 2017;8:97. https://doi.org/10.3389/fphys.2017.00097
16. Gonzalez-Menendez P, Hevia D, Mayo JC, Sainz RM. The dark side of glucose transporters in prostate cancer: Are they a new feature to characterize carcinomas? Int J Cancer. 2018;142(12):2414-2424. https://doi.org/10.1002/ijc.31165
17. Hirano H, Ide H, Lu Y, Inoue Y, Okada H, Horie S. Impact of Pretreatment Total Cholesterol Level Is Associated With Metastasis of Prostate Cancer. Am J Mens Health. 2020;14(2):1557988320918788. https://doi.org/10.1177/1557988320918788
18. Catalona WJ. Prostate Cancer Screening. Med Clin North Am. 2018;102(2):199-214. https://doi.org/10.1016/j.mcna.2017.11.001
19. Watts EL, Perez-Cornago A, Knuppel A, Tsilidis KK, Key TJ, Travis RC. Prospective analyses of testosterone and sex hormone-binding globulin with the risk of 19 types of cancer in men and postmenopausal women in UK Biobank. Int J Cancer. 2021;149(3):573-584. https://doi.org/10.1002/ijc.33555
Review
For citations:
Smirnov A.V., Gruzdeva O.V., Pomeshkin E.V., Bragin-Maltsev A.I. Dyslipidemia and risk of prostate canсer in patients with urologic diseases. Fundamental and Clinical Medicine. 2022;7(1):42-52. (In Russ.) https://doi.org/10.23946/2500-0764-2022-7-1-42-52
Views:
358
Email this article 